

TYSABRI (Natalizumab) ORDER FORM

REFERRAL TYPE

New Referral
 Order Renewal
 Restart
 Frequency Change
 Dosage Change

PREFERRED LOCATION

<input type="checkbox"/> 2730 University Blvd. West Suite 714 Wheaton, MD 20902	<input type="checkbox"/> 14995 Shady Grove Road Suite 250 Rockville, MD 20850	<input type="checkbox"/> 5454 Wisconsin Avenue Suite 600 Chevy Chase, MD 20815
<input type="checkbox"/> 18111 Prince Philip Drive Suite 323 Olney, MD 20832	<input type="checkbox"/> 71 Thomas Johnson Drive Frederick, MD 21702	<input type="checkbox"/> 2021 K Street, NW Suite 300 Washington, DC 20006
	<input type="checkbox"/> 3027 Javier Road Suite 2 Fairfax, VA 22031	

PATIENT INFORMATION

Name:	DOB:	Email:
Address:	Weight:	Phone:
	KG LBS	

REFERRING PHYSICIAN INFORMATION

Name:	NPI:
Office Contact Name:	Phone:
	Fax:
Address:	

TYSABRI ORDER

We do not accept off-label diagnoses, dosages, or frequencies.

Dosing/Frequency:

300mg IV every 4 weeks

Diagnosis:

G35—Multiple Sclerosis

Please identify the type of MS the patient has been diagnosed with:

Relapsing-remitting MS
 Secondary-progressive MS
 Primary-progressive MS
 Progressive-relapsing MS

K50.00—Crohn's disease of small intestine with complications

K50.10—Crohn's disease of large intestine w/o complication

Other Diagnosis: _____ ICD-10 Code (Required): _____

Special Instructions:

Physicians Signature: _____	Date: _____ (Order is Valid for One Year)
-----------------------------	--

REQUIRED DOCUMENTATION

Please fax the following documents and records:

- | | |
|---|---|
| <ul style="list-style-type: none"> ● Patient Demographics ● Two most recent office notes (Supporting the DX and treatment ordered) ● Most recent labs that include values for: <ul style="list-style-type: none"> ● CMP and CBC ● JCV Antibody test | <ul style="list-style-type: none"> ● Copy of the patient's insurance card(s) – front and back ● Medication History ● For continuation of treatment, include the last infusion note ● Most recent MRI report |
|---|---|

We will contact the patient and schedule their treatment once our benefit investigation and any prior authorizations have been completed.